Background: Bloodstream infections (BSI) cause substantial morbidity and mortality.

Aim: We explored the role of causative pathogens and patient characteristics on the outcome of community-acquired (CA) and healthcare-associated (HA) BSI, with particular interest in early death.

Methods: We used national register data to identify all BSI in Finland during 2004–18. We determined the origin of BSI, patients’ underlying comorbidities and deaths within 2 or 30 days from specimen collection. A time-dependent Cox model was applied to evaluate the impact of patient characteristics and causative pathogens on the hazard for death at different time points.

Results: A total of 173,715 BSI were identified; 22,474 (12.9%) were fatal within 30 days and, of these, 6,392 (28.4%) occurred within 2 days (7.9 deaths/100,000 population). The 2-day case fatality rate of HA-BSI was higher than that of CA-BSI (5.4% vs 3.0%). Patients who died within 2 days were older than those alive on day 3 (76 vs 70 years) and had more severe comorbidities. Compared with other BSI, infections leading to death within 2 days were more often polymicrobial (11.8% vs 6.3%) and caused by *Pseudomonas aeruginosa* (6.2% vs 2.0%), fungi (2.9% vs 1.4%) and multidrug-resistant (MDR) pathogens (2.2% vs 1.8%), which were also predictors of death within 2 days in the model.

Conclusions: Overrepresentation of polymicrobial, fungal, *P. aeruginosa* and MDR aetiology among BSI leading to early death is challenging concerning the initial antimicrobial treatment. Our findings highlight the need for active prevention and prompt recognition of BSI and appropriate antimicrobial treatment.

Introduction

Bloodstream infections (BSI) are a major health concern. According to a systematic review published in 2013, nearly 2 million BSI episodes and 250,000 deaths from BSI were estimated to occur annually in North America and Europe combined [1]. Despite advances in antimicrobial therapy and intensive care, mortality of BSI remains high, with 1-month case fatality rates of ca 10–19% for community-acquired BSI (CA-BSI) and even higher rates, 17–28%, for healthcare-associated BSI (HA-BSI) [2-6].

Previous studies have shown that a marked proportion, approximately one third of BSI-associated deaths occur early, within 2 days after the positive blood culture specimen [7-9]. To our knowledge, only one previous population-based study has reported 2-day case fatality rates of BSI, yet this study presents data from 1992–97 and consists of solely CA-BSI [7]. Possible predisposing factors for early mortality have not been studied; however, delayed diagnosis, inappropriate antimicrobial treatment, and the patient’s overall condition may contribute to an early fatal outcome of BSI. In general, the initial antimicrobial treatment of BSI is challenging since the confirmation of the causative pathogen and its susceptibility are typically not known until the second day after collecting blood cultures. Thus, some BSI-associated deaths occur before the definitive results from the blood cultures are known.

Our recent population-based study from Finland showed a twofold increase in the incidence and mortality of BSI during 2004–18, which is presumably related to ageing of the population and the rising burden of underlying medical conditions [10]. However, the 30-day case fatality rate remained steady over time (12.6–13.0%). In the present study, we used the same national laboratory-based surveillance data linked to other national registers to analyse all BSI in Finland during 2004–18 with the aim of evaluating the role of different factors, such as comorbidity and causative pathogens, on the outcome of BSI of both community and healthcare origin, with focus on early death (≤ 2 days).
| Characteristics                  | All BSI n = 173,715 | Community-acquired BSI n = 123,232 | Healthcare-associated BSI n = 50,483 | p value |
|---------------------------------|---------------------|------------------------------------|-------------------------------------|---------|
| **Sex**                         |                     |                                    |                                     | < 0.001 |
| Male                            | 90,231 (51.9)       | 61,619 (50.0)                     | 28,612 (56.7)                      |         |
| Female                          | 83,484 (48.1)       | 61,613 (50.0)                     | 21,871 (43.3)                      |         |
| **Age (years)**                 |                     |                                    |                                     | < 0.001 |
| Median (range)                  | 70 (0–110)          | 70 (0–110)                        | 71 (0–104)                         | < 0.001 |
| Group                           |                     |                                    |                                     |         |
| < 20                            | 8,943 (5.1)         | 6,313 (5.1)                       | 2,630 (5.2)                        |         |
| 20–69                           | 76,062 (43.8)       | 54,898 (44.5)                     | 21,164 (41.9)                      |         |
| ≥ 70                            | 88,710 (51.1)       | 62,021 (50.3)                     | 26,689 (52.9)                      |         |
| **Charlson comorbidity index**  |                     |                                    |                                     | < 0.001 |
| Median (range)                  | 1 (0–15)            | 1 (0–15)                          | 2 (0–15)                           | < 0.001 |
| Score                           |                     |                                    |                                     |         |
| 0                               | 70,328 (40.5)       | 57,883 (47.0)                     | 12,445 (24.7)                      |         |
| 1–2                             | 66,364 (38.2)       | 43,110 (35.0)                     | 23,254 (46.1)                      |         |
| ≥ 3                             | 37,023 (21.3)       | 22,239 (18.0)                     | 14,784 (29.3)                      |         |
| **Causative pathogen**          |                     |                                    |                                     | < 0.001 |
| Gram-positive bacteria           | 79,960 (46.0)       | 55,718 (45.2)                     | 24,242 (48.0)                      |         |
| Staphylococcus aureus           | 22,297 (12.8)       | 14,596 (11.8)                     | 7,701 (15.3)                       |         |
| Coagulase-negative staphylococci| 14,114 (8.1)        | 7,763 (6.3)                       | 6,351 (12.6)                       |         |
| Beta-haemolytic streptococci    | 13,068 (7.5)        | 11,427 (9.3)                      | 1,641 (3.3)                        |         |
| Streptococcus pneumoniae        | 11,472 (6.6)        | 10,309 (8.4)                      | 1,163 (2.3)                        |         |
| Enterococci                     | 7,348 (4.2)         | 3,211 (2.6)                       | 4,137 (8.2)                        |         |
| Viridans streptococci           | 5,538 (3.2)         | 4,121 (3.3)                       | 1,417 (2.8)                        |         |
| Other Gram-positive bacteria     | 6,123 (3.5)         | 4,291 (3.5)                       | 1,832 (3.6)                        |         |
| Gram-negative bacteria           | 79,520 (45.8)       | 59,455 (48.2)                     | 20,065 (39.7)                      | < 0.001 |
| Escherichia coli                | 50,188 (28.9)       | 40,103 (32.5)                     | 10,085 (20.0)                      |         |
| Klebsiella sp.                  | 9,025 (5.2)         | 6,220 (5.0)                       | 2,805 (5.6)                        |         |
| Pseudomonas aeruginosa          | 3,670 (2.1)         | 1,752 (1.4)                       | 1,918 (3.8)                        |         |
| Enterobacter sp.                | 3,097 (1.8)         | 1,800 (1.5)                       | 1,297 (2.6)                        |         |
| Other Gram-negative bacteria     | 13,540 (7.8)        | 9,580 (7.8)                       | 3,960 (7.8)                        |         |
| Fungi                           | 2,547 (1.5)         | 418 (0.3)                         | 2,129 (4.2)                        |         |
| Candida albicans                | 1,601 (0.9)         | 219 (0.2)                         | 1,382 (2.7)                        |         |
| Non-albicans Candida            | 915 (0.5)           | 193 (0.2)                         | 722 (1.4)                          |         |
| Other fungi                     | 31 (0.02)           | 6 (0.005)                         | 25 (0.05)                          |         |
| Other pathogens (not classified) | 341 (0.2)           | 229 (0.2)                         | 112 (0.2)                          |         |
| Polymicrobial BSI               | 11,347 (6.5)        | 7,412 (6.0)                       | 3,935 (7.8)                        |         |
| MDR pathogens b                 | 3,150 (1.8)         | 1,983 (1.6)                       | 1,167 (2.3)                        | < 0.001 |

BSI: bloodstream infection; MDR: multidrug-resistant.

Differences between community-acquired and healthcare-associated BSI were evaluated with the chi-squared test for categorial variables and with the Kruskal-Wallis test for continuous variables.

* The p value was determined for the differences in the main groups of causative pathogens, i.e. Gram-positive bacteria, Gram-negative bacteria, fungi, other pathogens and polymicrobial BSI.

b MDR pathogens include extended-spectrum beta-lactamase-producing (ESBL) *Escherichia coli* and *Klebsiella pneumoniae*, methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus* (VRE) and carbapenem-resistant Enterobacteriaceae (CRE).
Materials and methods

Study setting and population

The healthcare system in Finland (population: 5.2 million in 2004 and 5.5 million in 2018 [11]) is organised into 20 healthcare districts, which include a total of five tertiary care hospitals, 15 secondary care hospitals and numerous primary care hospitals. All clinical microbiology laboratories notify bacterial and fungal isolates from blood samples, i.e. BSI, to the National Infectious Disease Register (NIDR). The notifications are reported electronically and include the following information: specimen date, pathogen, patient date of birth, sex, place of residence, and national identity code. Multiple notifications of the same pathogen containing the same identity code, i.e. referring to the same person, are merged into a case if they occur within 3 months of each other.

In this retrospective cohort study, we used NIDR data to identify all BSI in Finland during 2004–18. Only BSI with valid identity codes were included in the study (n=587 excluded) (flow chart of the data in [10], Figure 1). Duplicate notifications (same specimen date, pathogen, and identity code) were excluded (n=155). Information on the hospitalisation of the patient, including origin of the infection, i.e. CA-BSI vs HA-BSI, and current and prior (within 1 year) diagnosis codes were obtained by linkage to the National Hospital Discharge Register (HILMO).

Definitions

BSI was defined as the occurrence of viable bacteria or fungi in the blood evidenced by positive blood cultures. Polymicrobial BSI was defined as isolation of more than one bacterial or fungal species in blood cultures within 2 days.

BSI was classified as healthcare-associated (HA) if the first blood culture was obtained more than 2 days after admission to the hospital or within 2 days of discharge [12]. Patients with a BSI who were transferred from other healthcare facilities, including nursing homes, were also classified as having a HA-BSI. Patients with CA-BSI had not previously been hospitalised and their blood culture specimen was obtained within 2 days of hospital admission.

Comorbid illness was defined by using a validated algorithm for the Charlson comorbidity index (CCI) based on the International Classification of Diseases, 10th revision [13,14]. Three levels of comorbidity were defined by the CCI scores: low (score 0) for patients with no reported underlying diseases included in the CCI, medium (score 1–2) and high (score>2) [15,16].

Multidrug-resistant pathogens

The interpretation of susceptibility data of causative pathogens was performed in the clinical microbiology laboratories by using the CLSI standard for samples collected before year 2011 and, afterwards, according to the EUCAST clinical breakpoints [17]. The following bacteria with susceptibility data notified to the NIDR were defined as multidrug-resistant (MDR) pathogens: methicillin-resistant *Staphylococcus aureus* (MRSA) (starting year 1995), vancomycin-resistant *Enterococcus* (VRE) (1995), extended-spectrum beta-lactamase-producing (ESBL) *Escherichia coli* and *Klebsiella pneumoniae* (2008), and carbapenem-resistant *Enterobacteriaceae* (CRE) (2015). ESBL- *E. coli* and ESBL-*K. pneumoniae* were defined as resistant or intermediately susceptible to third-generation cephalosporins, and CRE as *E. coli, K. pneumoniae* and *Enterobacter* sp. resistant or intermediately susceptible to carbapenems.

Outcome

The case fatality rate at 2 or 30 days (1 month) after withdrawal of the first blood specimen with a positive culture of a particular patient was determined from the Population Information System by linkage with the identity code. All deaths occurring within 2 days after collection of the specimen yielding the first positive blood culture (day 0) were referred to as early deaths.

Analyses and statistics

The average annual 2-day and 30-day mortality rates (early and overall deaths/100,000 population, respectively) were calculated according to the total number of deaths and population during 2004–18; population data was retrieved from Statistics Finland [11]. Univariate analysis of categorical variables was done with the chi-squared test, using Yates’s correction or Fisher’s exact test, as appropriate. The differences in distributions between continuous variables were tested by the Kruskal-Wallis test. A time-dependent Cox model was applied to evaluate the effects of patient characteristics and causative pathogens on the hazard for death within different time points (within 2 or 3–30 days after the positive blood culture). Data was analysed using SPSS Statistics version 25 (IBM) and Stata 16 (StataCorp).

Results

Study population and causative pathogens

During 2004–18, a total of 173,715 BSI among 147,953 patients were identified; 70.9% were CA-BSI and 29.1% HA-BSI (Table 1). Of the patients with HA-BSI, 56.7% were male, whereas no sex difference was noted in CA-BSI. The percentage of persons aged ≥70 years and the proportion of patients with high CCI (score>2) were significantly greater among HA-BSI compared with CA-BSI (52.9% vs 50.3% and 29.3% vs 18.0%, respectively).

The most common causative pathogens of CA-BSI were *E. coli, S. aureus*, beta-haemolytic streptococci, and *Streptococcus pneumoniae*. Among HA-BSI, more *S. aureus*, coagulase-negative *staphylococci* (CNS) and enterococci were observed, but fewer *E. coli* BSI. Altogether, 3,150 BSI (1.8%) were caused by MDR pathogens (Table 1); 1.2% of all BSI were caused
**Table 2**

Case fatality rate of bloodstream infections at different time points by patient characteristics, origin of infection and causative pathogens, Finland, 2004–2018 (n = 173,715 bloodstream infections)

| Characteristics | All BSI n=173,715 | 2-day case fatality | 30-day case fatality |
|-----------------|-------------------|---------------------|----------------------|
|                 | n                  | %                   | n                    | %                   |
| **Sex**         |                   |                     |                      |                     |
| Male            | 90,231             | 3,533               | 3.9                  | 12,399              | 13.7               |
| Female          | 83,484             | 2,859               | 3.4                  | 10,075              | 12.1               |
| **Age group (years)** |             |                     |                      |                     |
| All             | 173,715            | 6,392               | 3.7                  | 22,474              | 12.9               |
| <20             | 8,943              | 96                  | 1.1                  | 211                 | 2.4                |
| 20–69           | 76,062             | 2,217               | 2.9                  | 7,341               | 9.7                |
| ≥70             | 88,710             | 4,079               | 4.6                  | 14,022              | 16.8               |
| **Charlson comorbidity index** |             |                     |                      |                     |
| Score           |                   |                     |                      |                     |
| 0               | 70,328             | 1,379               | 2.0                  | 4,163               | 5.9                |
| 1–2             | 66,364             | 2,768               | 4.2                  | 9,799               | 14.8               |
| >2              | 37,023             | 2,245               | 6.1                  | 8,512               | 23.0               |
| **Origin of infection** |             |                     |                      |                     |
| Community-acquired BSI | 123,232            | 3,667               | 3.0                  | 12,056              | 9.8                |
| Healthcare-associated BSI | 50,483            | 2,725               | 5.4                  | 10,418              | 20.6               |
| **Causative pathogen** |             |                     |                      |                     |
| Gram-positive bacteria | 79,960            | 2,687               | 3.4                  | 10,542              | 13.2               |
| Staphylococcus aureus | 22,297            | 865                 | 3.9                  | 3,845               | 17.2               |
| Coagulase-negative staphylococci | 14,114            | 286                 | 2.0                  | 1,519               | 10.8               |
| Beta-haemolytic streptococci | 13,068            | 417                 | 3.2                  | 1,140               | 8.7                |
| Streptococcus pneumoniae | 11,472            | 441                 | 3.8                  | 1,055               | 9.2                |
| Enterococci      | 7,348              | 224                 | 3.0                  | 1,421               | 19.3               |
| Viridans streptococci | 5,538              | 134                 | 2.4                  | 587                 | 10.6               |
| Other Gram-positive bacteria | 6,123             | 320                 | 5.2                  | 975                 | 16.0               |
| Gram-negative bacteria | 79,520            | 2,756               | 3.5                  | 8,687               | 10.9               |
| Escherichia coli | 50,188             | 1,260               | 2.5                  | 4,126               | 8.2                |
| Klebsiella sp.   | 9,025              | 343                 | 3.8                  | 1,191               | 13.2               |
| Pseudomonas aeruginosa | 3,670             | 398                 | 10.8                 | 863                 | 23.5               |
| Enterobacter sp. | 3,097              | 105                 | 3.4                  | 424                 | 13.7               |
| Other Gram-negative bacteria | 13,540           | 650                 | 4.8                  | 2,083               | 15.4               |
| **Fungi**       |                   |                     |                      |                     |
| Candida albicans | 1,601              | 108                 | 6.7                  | 553                 | 34.5               |
| Non-albicans Candida | 915               | 76                  | 8.3                  | 304                 | 33.2               |
| Other fungi      | 31                 | 1                   | 3.2                  | 7                   | 22.6               |
| Other pathogens (not classified) | 341              | 8                   | 2.3                  | 39                  | 11.4               |
| Polymicrobial BSI | 11,347             | 756                 | 6.7                  | 2,342               | 20.6               |
| MDR pathogens*   | 3,150              | 142                 | 4.5                  | 526                 | 16.7               |

BSI: bloodstream infection; MDR: multidrug-resistant.
* MDR pathogens include extended-spectrum beta-lactamase-producing (ESBL) *Escherichia coli* and *Klebsiella pneumoniae*, methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus* (VRE), and carbapenem-resistant *Enterobacteriaceae* (CRE).
Case fatality rates at different time points
Of all BSI, 6,392 (3.7%) were fatal within 2 days (7.9 early deaths/100,000 population, range by year: 6.1–10.1) and 22,474 (12.9%) within 30 days (27.9 overall deaths/100,000 population, range by year: 19.5–39.0); among CA-BSI, 30.4% (3,667/12,056) of all deaths occurred within 2 days and among HA-BSI 26.2% (2,725/10,418). The 2-day and 30-day case fatality rates were higher for HA-BSI than for CA-BSI (5.4% vs 3.0% and 20.6% vs 9.8%), and slightly higher for males than for females (Table 2). The case fatalities increased with age and with rising CCI; for persons aged ≥70 years the case fatalities were over 1.7-fold higher compared with younger and for patients with high CCI over three times greater compared with those with low CCI. Concerning causative pathogens, the highest 2-day and 30-day case fatality rates were noted for *P. aeruginosa* (10.8% and 23.5%) and fungi (7.3% and 33.9%), and for polymicrobial BSI (6.7% and 20.6%). For MDR pathogens, the 2-day and 30-day case fatality rates were 4.5% and 16.7%, respectively.

Predictors of early death
Patients who died early, within 2 days, were older than those who were alive at day 3 (median age: 76 vs 70 years) (Table 3). The proportion of HA-BSI and patients with high CCI were greater in BSI leading to early death compared with those of other BSI (42.6% vs 28.5% and 35.1% vs 20.8%, respectively). *E. coli* was the most common causative pathogen of BSI leading to early death (19.7%), followed by *S. aureus* (13.5%), *S. pneumoniae* (6.9%), beta-haemolytic streptococci (6.5%) and *P. aeruginosa* (6.2%). The 2-day case fatality rates and proportions of fatal episodes by causative pathogens are presented in the Supplement (Supplementary Table S1: all BSI, Supplementary Table S2: CA-BSI and Supplementary Table S3: HA-BSI). Polymicrobial, *P. aeruginosa* and fungal BSI were more common among patients who died early compared with patients who were alive at day 3 (11.8% vs 6.3%, 6.2% vs 2.0% and 2.9% vs 1.4%, respectively), as were also BSI caused by MDR pathogens (2.2% vs 1.8%).

Trends in bloodstream infections leading to early death
During 2004–18, a slight decrease was noted in the 2-day case fatality rate, from 4.1% (317/7,819) to 3.3% (557/17,009) in all BSI, from 3.3% (174/5,227) to 2.7% (358/13,284) in CA-BSI and from 5.5% (143/2,592) to 5.3% (199/3,725) in HA-BSI. The median age of the BSI patients who died early increased from 73 to 79 years and the percentage of those with high CCI rose from 29% to 39% during 2004–18. The proportion of *E. coli* BSI leading to early death increased from 18.3% (58/317) to 20.8% (116/557) and *S. aureus* BSI from 12.6% (40/317) to 16.5% (92/557), whereas *S. pneumoniae* BSI decreased from 13.2% (42/317) to 3.6% (20/557) during 2004–18. The proportion of ESBL-E. coli BSI of all *E. coli* BSI leading to early death rose from 1.4% (1/73) to 11.2% (13/116), whereas the proportion of MRSA BSI of *S. aureus* BSI leading to early death declined slightly, from 2.5% (1/40) to 2.2% (2/92).

Risk factors for death of community-acquired and healthcare-associated bloodstream infections within 2 or 30 days
To evaluate possible risk factors for BSI fatality, we conducted a time-dependent Cox model demonstrating the effect of patient characteristics and causative pathogens on the hazard for death in two outcome groups, death within 2 or 3–30 days; CA-BSI and HA-BSI were analysed separately. Sex and CCI, together with the most common causative pathogens of all BSI (*E. coli* and *S. aureus*) and those associated with the highest 2-day case fatalities (*P. aeruginosa*, fungi and polymicrobial BSI), were included in the model. A clustering effect of healthcare districts was taken into account by robust standard errors, and calendar year was included as a continuous variable. The effect of age on risk of death was presented by a 10-year increase in age. Increasing age and CCI were risk factors for death in both outcome groups and among both CA-BSI and HA-BSI (Figure); the highest hazard ratio (HR: 3.19) was noted among patients with CA-BSI leading to death within 3–30 days with high CCI (Figure, panel D). Male sex was associated with a slightly higher hazard for death in both outcome groups among CA-BSI (Figure, panels C and D). In both HA-BSI and CA-BSI leading to death within 2 days, the highest hazards for death related to specific pathogens were noted for *P. aeruginosa* (HR: 2.74 and 2.07, respectively) (Figure, panels A and C). For BSI with a fatal outcome within 3–30 days, the highest hazards for death were observed for *S. aureus* in CA-BSI (HR: 1.82) (Figure, panel D) and for fungi in HA-BSI (HR 2.32) (Figure, panel B). The hazard ratios of polymicrobial BSI were similar between the outcome groups (Figure, panels A–D). The hazard ratios were higher for ESBL-E. coli compared with non-ESBL-E. coli both within 2 or 3–30 days (HR: 1.28–1.54 vs 0.58–0.87) (Figure, panels A–D).

Discussion
Our population-based study of over 170,000 BSI in Finland during 2004–18 offers a comprehensive overview on the outcome, particularly early death, of both CA-BSI and HA-BSI. The 30-day case-fatality rate was 12.9%, and nearly one third of these deaths occurred early, within 2 days. We noted higher 2-day and 30-day case fatalities for HA-BSI compared with CA-BSI. Older age and a greater burden of comorbidities were associated with early BSI mortality. BSIs with early fatal outcome were more often polymicrobial and caused by *P.
Table 3
Predictors of early death caused by bloodstream infection in Finland during 2004–2018 (n = 173,715 bloodstream infections)

| Characteristics                          | Death within 2 days | Alive at day 3 | p value |
|------------------------------------------|---------------------|----------------|---------|
|                                          | n = 6,392           | n = 167,323    |         |
| Sex                                      |                     |                |         |
| Male                                     | 3,533               | 86,698         | <0.001 |
| Female                                   | 2,859               | 80,625         |         |
| Age (years)                              |                     |                |         |
| Median (range)                           | 76 (0–103)          | 70 (0–110)     | <0.001 |
| Charlson comorbidity index               |                     |                |         |
| Median (range)                           | 2 (0–14)            | 1 (0–15)       | <0.001 |
| Score                                    |                     |                |         |
| 0                                        | 1,379               | 68,949         | 41.2    |
| 1–2                                      | 2,768               | 63,596         | 38.0    |
| >2                                       | 2,245               | 34,778         | 20.8    |
| Origin of infection                      |                     |                | <0.001 |
| Community-acquired BSI                   | 3,667               | 119,565        | 71.5    |
| Healthcare-associated                    | 2,725               | 47,758         | 28.5    |
| Causative pathogen                       |                     |                |         |
| Gram-positive bacteria                    | 2,687               | 77,273         | 46.1    |
| Staphylococcus aureus                    | 865                 | 21,432         | 12.8    |
| Coagulase-negative staphylococci         | 286                 | 13,828         | 8.3     |
| Beta-haemolytic streptococci             | 417                 | 12,651         | 7.6     |
| Streptococcus pneumoniae                 | 441                 | 11,031         | 6.6     |
| Enterococci                              | 224                 | 7,124          | 4.3     |
| Viridans streptococci                    | 134                 | 5,404          | 3.2     |
| Other Gram-positive bacteria              | 320                 | 5,803          | 3.5     |
| Gram-negative bacteria                    | 2,756               | 76,764         | 45.9    |
| Escherichia coli                         | 1,260               | 48,928         | 29.2    |
| Klebsiella sp.                           | 343                 | 8,682          | 5.2     |
| Pseudomonas aeruginosa                   | 398                 | 3,272          | 2.0     |
| Enterobacter sp.                         | 105                 | 2,992          | 1.8     |
| Other Gram-negative bacteria              | 650                 | 12,890         | 7.7     |
| Fungi                                    | 185                 | 2,362          | 1.4     |
| Candida albicans                         | 108                 | 1,493          | 0.9     |
| Non-albicans Candida                     | 76                  | 839            | 0.5     |
| Other fungi                              | 1                   | 30             | 0.02    |
| Other pathogens (not classified)         | 8                   | 333            | 0.2     |
| Polymicrobial BSI                        | 756                 | 10,591         | 6.3     |
| MDR pathogens                           | 142                 | 3,008          | 1.8     |

BSI: bloodstream infection; MDR: multidrug-resistant.

Differences between the outcome groups were evaluated with the chi-squared test for categorical variables and with the Kruskal-Wallis test for continuous variables.

* A p value was determined for the differences in the main groups of causative pathogens, i.e. Gram-positive bacteria, Gram-negative bacteria, fungi, other pathogens and polymicrobial BSI.

** MDR pathogens include extended-spectrum beta-lactamase-producing (ESBL) Escherichia coli and Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and carbapenem-resistant Enterobacteriaceae (CRE).
Figure
Hazard ratios for death of healthcare-associated bloodstream infections (n = 50,483) and community-acquired bloodstream infections (n = 123,232) according to patient characteristics and causative pathogens in different outcome groups, Finland, 2004–2018

A. HA-BSI hazard ratio 0–2 days (n = 2,725)

B. HA-BSI hazard ratio 3–30 days (n = 7,693)

C. CA-BSI hazard ratio 0–2 days (n = 3,667)

D. CA-BSIs within 3–30 days (n = 8,389)

BSI: bloodstream infection; CA-BSI: community-acquired bloodstream infection; ESBL-E. coli: extended-spectrum beta-lactamase-producing Escherichia coli; HA-BSI: healthcare-associated bloodstream infection.

Black dots indicate hazard ratios and vertical lines signify 95% confidence intervals.
P. aeruginosa, fungi and MDR pathogen compared with other BSI.

We conducted the time-dependent Cox model separately for HA-BSI and CA-BSI based on the knowledge that hospitalised patients are older and have more severe underlying conditions than patients who have acquired a BSI in the community. Also, the treatment guidelines for empiric antimicrobial therapy differ between CA-BSI and HA-BSI based on the differences in causative pathogens. Our model allowed direct comparison of hazards for death concerning causative pathogens of BSI in two outcome groups, as the effect of increasing age and burden of comorbidity was similar between the groups. Although E. coli and S. aureus were the most common causative pathogens of all BSI and of those leading to death within 2 days, they were not predictors of early death. However, P. aeruginosa aetiology was distinctly associated with increased risk for early death, whereas polymicrobial and fungal BSI were associated with a fatal outcome both within 2 days and 3–30 days. Polymicrobial BSI accounted for over 10% of all BSI leading to early death, and P. aeruginosa and fungal BSI together for over 15% of HA-BSI leading to early death. The empiric antimicrobial therapy of these BSI is a challenge for clinicians, as the lack of antifungal or broad-spectrum coverage may contribute to early fatality. In fact, a previous study showed that inappropriate initial treatment of P. aeruginosa BSI was associated with increased hospital mortality [18]. In our former population-based case series of BSI leading to early death in Southern Finland in 2007, empiric antimicrobial therapy was inappropriate in nearly 30% of the BSI; in 12% of CA-BSI and in 50% of HA-BSI [19]. These inappropriately treated BSI leading to early death were mainly caused by intrinsically resistant Gram-negative bacteria (most commonly P. aeruginosa). Consistently, previous reports demonstrate that healthcare-associated status in general is a predictor of ineffective empiric antimicrobial treatment of BSI [20] and of 30-day BSI mortality [5,21].

In our study, the 2-day case fatalities for CA-BSI and HA-BSI were 3.0% and 5.4%, respectively; 30.4% of the deaths among CA-BSI and 26.2% among HA-BSI occurred early. In a survey of community-onset BSI from Calgary, Canada during 2003–07, 38% of the deaths occurred by day 2, equalling a 2-day case fatality rate of 4.7% [8], whereas a slightly higher 2-day case fatality rate (7.2%) was presented in an older population-based cohort study of CA-BSI from North Jutland, Denmark, during 1992–97 [7]. The 30-day case fatality rate observed in the present study (12.9%) is comparable to rates in recent population-based reports (12.8–16.9%) [5,22,23]. Our 2-day and 30-day case fatalities were higher for HA-BSI than for CA-BSI. This is in line with findings from a Swedish study spanning from 2000–13 that demonstrated a 30-day case fatality rate of 17.2% for hospital-acquired BSI and 10.6% for community-onset BSI [5]. In our study, the patients who died early had more underlying diseases and were older compared with other BSI patients, which was also noted in our previous case series [19]. In a Danish survey, only 2% of the BSI patients who died early had no predisposing underlying condition, and these patients were older than survivors [24]. Similarly, former studies have shown that rising age and comorbidity are associated with 30-day BSI mortality [5,7,21,25-27].

Overall, the 2-day case fatality rate of BSI in our study decreased slightly during 2004–18, from 4.1% to 3.3%, possibly indicating advancements in recognition and accuracy of empiric antimicrobial treatment of BSI. In a Danish survey of CA-BSI during 1992–97, the 2-day case fatalities for given pathogens were considerably higher compared with those of CA-BSI in our study; for S. pneumoniae 9.3% vs 3.6%, respectively, for S. aureus 9.0% vs 3.1%, for E. coli 6.3% vs 2.0%, and for polymicrobial BSI 10.7% vs 5.9% [7]. The descending overall 2-day case fatality rate noted in the present study might reflect changes in causative pathogens of BSI leading to early death over time, such as the increase in the proportion of E. coli BSI but also the decline in S. pneumoniae BSI. The observed reduction in S. pneumoniae BSI is probably associated with the introduction of the pneumococcal vaccine to the childhood immunisation schedule [28,29]. We observed a distinct ascending trend in the percentage of ESBL-E. coli BSI leading to early death during 2004–18. However, the overall proportion of BSI caused by MDR pathogens in our study was low, 2.2% of BSI leading to early death and 1.8% of all BSI, compared with reports from North America and most of Europe excluding the Nordic countries [27,30,31]. Thus, MDR pathogens have not played a substantial role in fatal outcome of BSI in Finland thus far, yet the global threat of antimicrobial resistance may potentially worsen the outcome of BSI in the future.

There are certain limitations in our study. Firstly, we did not have information on possible delays in recognition of the infection and commencement of the treatment, nor data on whether the antimicrobial therapy was appropriate. Delayed and ineffective initial treatment are associated with increased BSI mortality, as demonstrated in previous reports [26,32-34]. In our previous study of BSI leading to early death, the time from symptom onset to administration of antimicrobial therapy was longer in CA-BSI compared with HA-BSI referring to probable delays in seeking medical care [19]. Secondly, we lacked data on detailed clinical features, such as severity of infection (e.g. the respiratory tract as a focus of infection), and information on the role of BSI in the chain of morbid events and on the main cause of death. However, among patients who died early, BSI may have been at least a contributing factor. We did not have data on patients’ underlying medical conditions other than the ones included in the CCI, nor information on a possible do-not-resuscitate (DNR) order, which likely have influenced the outcome. In fact, nearly one third of the BSI patients who died early in our previous case series had either a rapidly fatal underlying condition
or a prior DNR order indicating a poor overall condition, and it is probable that most of these deaths were inevitable [19]. Furthermore, we lacked information on behavioural predisposing factors, such as overweight and smoking behaviour, which may affect the outcome [35]. Thirdly, we had limited information on antimicrobial resistance of the causative pathogens, for example, no susceptibility data was available concerning *P. aeruginosa* and *Acinetobacter* sp. Lastly, it is possible that some HA-BSI were inaccurately interpreted as CA-BSI since the hospital discharge register contains data on day surgery only (not all outpatient invasive procedures) and on direct transfers between healthcare facilities. Moreover, the timeframe, blood cultures obtained within 2 days of hospital discharge, for the definition of HA-BSI in the study was quite strict possibly leading to underestimation of HA-BSI.

### Conclusion

In view of ageing of population in Finland, as in most other industrialised countries, BSI will constitute a major health burden in the future with a risk of fatal outcome, especially among vulnerable patients, elderly people and those with severe comorbidity. In our study, a notable proportion of BSI patients died early, and probably at least some of those deaths were inevitable. However, one fifth of those who died early had no recorded underlying medical condition, which emphasises the importance of rapid recognition of BSI and prompt initiation of adequate antimicrobial treatment according to the origin of the infection. The 2-day case fatality rate of BSI might potentially be used as an indicator of effectiveness of the healthcare system and the treatment chain. The 2-day and 30-day case fatalities were higher for HA-BSI in the present study underlining the need for considerable efforts in prevention of BSI in healthcare facilities. Active surveillance of causative pathogens and their resistance trends is beneficial when composing local guidelines for empiric antimicrobial therapy of BSI. Although the proportion of BSI caused by MDR pathogens was low in our study, the growing problem of antimicrobial resistance causes concern worldwide. Further studies are needed to evaluate the impact of the COVID-19 pandemic on the incidence, outcome, and causative pathogens of BSI, particularly on the occurrence of resistant pathogens.

### Statements

**Ethical statement:** Permission to analyse and link data from the NIDR and HILMO was granted by the Ethics Committee of the Finnish Institute for Health and Welfare (THL/1349/6.02.00/2019).

**Funding statement:** This work was supported by the Finnish Cultural Foundation (grant number 00390532 to K.K.); the Finnish Medical Foundation (grant number 3986 to K.K.); the Finnish Society for Study of Infectious Diseases (grant 04/09/2019 to K.K.); the HUS Inflammation Center Research Fund (grant numbers Y1209TUTKK, Y1209INF01 to K.K.); and the State Funding for the Finnish University Hospitals. The funders had no role in study design, data collection and analysis, preparation of the manuscript, nor the decision to publish.

### Conflict of interest

K.K., J.O. and O.L. report no conflict of interest relevant to this article. K.S. has received fees for lectures from the Finnish Medical Society Duodecim, the Finnish Infection Prevention Society and the Finnish Society of Gastroenterology outside the submitted work. K.S. is the chairperson of the Finnish Infection Prevention Society. A.J. has received consulting fees from CSL Behring and fees for lectures from Astellas Pharma, Gilead Sciences, GSK, Sanofi, Thermo Fisher Scientific, and Orion Pharma outside the submitted work. A.J. reports board membership in Gilead Sciences, GSK, Sanofi, Filha and NSCMID.

### Authors’ contributions

OL, KS, AJ and KK conceptualised and designed the study. KK, JO and OL analysed and interpreted the data. KK wrote the manuscript draft. OL, KS, AJ and JO reviewed and edited the manuscript. All authors approved the final report.

### References

1. Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect. 2015;19(6):501-9. https://doi.org/10.1111/cmi.12915 PMID: 23473333
2. Rodríguez-Bravo J, López-Prieto MD, Portillo MM, Retamar P, Natera C, Nuño E, et al. Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. Clin Microbiol Infect. 2010;16(9):1458-63. https://doi.org/10.1111/j.1469-0691.2010.03089.x PMID: 19845694
3. Segard M, Nørgaard M, Dethlefsen C, Schenheyder HC. Temporal changes in the incidence and 30-day mortality associated with bacteremia in hospitalized patients from 1992 through 2006: a population-based cohort study. Clin Infect Dis. 2011;52(1):161-9. https://doi.org/10.1093/cid/ciq069 PMID: 21148521
4. Lenz R, Leal JR, Church DL, Gregson DB, Ross T, Laupland KB. The distinct category of healthcare associated bloodstream infections. BMC Infect Dis. 2012;12(1):85. https://doi.org/10.1186/1471-2334-12-85 PMID: 22487002
5. Holmbo M, Giske CG, Fredrikson M, Østholm Balkhed Å, Claesson C, Nilsson LE, et al. 14-Year survey in a Swedish county reveals a pronounced increase in bloodstream infections (BSI). Comorbidity - an independent risk factor for both BSI and mortality. PLoS One. 2016;11(8):e0166527. https://doi.org/10.1371/journal.pone.0166527 PMID: 27635663
6. Martínez Pérez-Crespo PM, López-Cortés LE, Retamar-Gentil P, García JFL, Vinuesa García D, León E, et al. Epidemiologic changes in bloodstream infections in Andalucía (Spain) during the last decade. Clin Microbiol Infect. 2021;27(2):283.e9-16. https://doi.org/10.1016/j.cmi.2020.05.015 PMID: 32470569
7. Pedersen G, Schenheyder HC, Sørensen HT. Source of infection and other factors associated with case fatality in community-acquired bacteremia—a Danish population-based cohort study from 1992 to 1997. Clin Microbiol Infect. 2003;9(8):793-802. https://doi.org/10.1016/S1469-0691(03)00599-X PMID: 14616959
8. Laupland KB, Svenson LW, Gregson DB, Church DL. Long-term mortality associated with community-onset bloodstream infection. Infection. 2011;39(5):405-10. https://doi.org/10.1007/s15010-011-0149-x PMID: 21706223
9. Skogberg K, Lyytikäinen O, Ölgren J, Nuorti JP, Ruutu P. Population-based burden of bloodstream infections in Finland. Clin Microbiol Infect. 2012;18(6):E170-6. https://doi.org/10.1111/j.1469-0691.2012.03845.x PMID: 22512663
10. Kontula KSK, Skogberg K, Ölgren J, Järvinen A, Lyytikäinen O. Population-based study of bloodstream infection incidence and mortality rates, Finland, 2004-2018. Emerg Infect Dis. 2021;27(10):2560-9. https://doi.org/10.3201/eid2710.204826 PMID: 34546161
conjugate vaccination on invasive pneumococcal disease among children in Finland. Vaccine. 2018;36(5):1934-40. https://doi.org/10.1016/j.vaccine.2018.03.001 PMID: 29526371

29. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Malbak K, Slotved HC, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59(8):1066-73. https://doi.org/10.1093/cid/ciu524 PMID: 25034271

30. de Kraker ME, Jarlier V, Monen JC, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clin Microbiol Infect. 2013;19(9):860-8. https://doi.org/10.1111/1469-0691.12028 PMID: 23039210

31. Diekema DJ, Hsueh PR, Pfaffer MA, Rolston KV, Sader HS, et al. The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother. 2019;63(2):e00355-19. https://doi.org/10.1128/AAC.00355-19 PMID: 31018062

32. Retamar P, Portillo MM, López-Prieto MD, Rodríguez-López F, de Cueto M, García MV, et al. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother. 2012;56(1):472-8. https://doi.org/10.1128/AAC.00621-11 PMID: 22005999

33. Pedersen G, Schønheyder HC, Østergaard C, Knudsen JD, Wehberg S, et al. Impact of appropriate empirical antibiotic treatment on recurrence and mortality in patients with bacteraemia: a population-based cohort study. BMC Infect Dis. 2017;17(1):122. https://doi.org/10.1186/s12879-017-2233-z PMID: 28166732

34. Kadir SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, et al. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis. 2021;21(5):521-31. https://doi.org/10.1016/S1473-3099(20)30477-1 PMID: 32916100

35. Paulsen J, Askim Å, Mohus RM, Mehl A, Dewan A, Solligård E, et al. Associations of obesity and lifestyle with the risk and mortality of bloodstream infection in a general population: a 15-year follow-up of 64,027 individuals in the HUNT Study. Int J Epidemiol. 2017;46(5):1573-81. https://doi.org/10.1093/ije/dyx091 PMID: 28657260

License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2022.